Galapagos NV (NASDAQ:GLPG) – Equities research analysts at Jefferies Group reduced their FY2018 earnings per share (EPS) estimates for shares of Galapagos in a report issued on Monday. Jefferies Group analyst P. Welford now forecasts that the biotechnology company will earn ($3.92) per share for the year, down from their prior forecast of ($3.07). Jefferies Group also issued estimates for Galapagos’ FY2019 earnings at ($4.31) EPS, FY2020 earnings at ($3.39) EPS, FY2021 earnings at ($7.50) EPS and FY2022 earnings at $2.60 EPS.
Other research analysts also recently issued reports about the company. BidaskClub raised Galapagos from a “hold” rating to a “buy” rating in a research note on Wednesday, January 31st. BTIG Research reaffirmed a “buy” rating and issued a $118.00 target price on shares of Galapagos in a report on Monday, November 20th. ValuEngine raised Galapagos from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research raised Galapagos from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $111.00.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. New York State Common Retirement Fund acquired a new stake in shares of Galapagos during the 2nd quarter worth approximately $166,000. Northern Trust Corp grew its holdings in shares of Galapagos by 2.9% during the 2nd quarter. Northern Trust Corp now owns 18,480 shares of the biotechnology company’s stock worth $1,414,000 after purchasing an additional 524 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Galapagos by 254.3% during the 2nd quarter. Royal Bank of Canada now owns 4,170 shares of the biotechnology company’s stock worth $319,000 after purchasing an additional 2,993 shares in the last quarter. Aperio Group LLC grew its holdings in shares of Galapagos by 22.2% during the 3rd quarter. Aperio Group LLC now owns 4,159 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 755 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new stake in shares of Galapagos during the 3rd quarter worth approximately $105,000. 19.49% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3228076/fy2018-earnings-estimate-for-galapagos-nv-glpg-issued-by-jefferies-group.html.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.